Instructions for Authors

Comprehensive guidance for Alzheimer's research manuscript preparation.

• Title Page: Full title, all authors with ORCID, affiliations, corresponding author, word count, funding
• Abstract: Structured with Background, Methods, Results, Conclusions; 5-7 keywords
• Introduction: Context, knowledge gap, objectives; cite foundational dementia literature
• Methods: Detailed protocols, diagnostic criteria used, statistical approaches, ethical approvals
• Results: Clear presentation with appropriate statistics and confidence intervals
• Discussion: Interpretation, limitations, clinical implications, future directions

Research involving dementia patients requires highest ethical standards. Document informed consent procedures, including provisions for patients with cognitive impairment and surrogate consent. IRB approval required. Include ethics committee protocol numbers.

• Submit figures as separate high-resolution files (300 dpi minimum)
• Patient images require documented consent
• Brain imaging should follow standardized atlases and color maps
• Tables should be editable with clear headers and footnotes
• Supplementary data welcome for extensive datasets

JART encourages data sharing where ethically permissible. Include data availability statement. Consider de-identified datasets for secondary analyses. Register systematic review protocols in PROSPERO.

Use Vancouver (numbered) citation style. Include DOIs. Cite NIA-AA, IWG, and ADNI guidelines where relevant.

Manuscripts must be written in clear, grammatical English suitable for international readers. Authors whose first language is not English should consider professional language editing. Use SI units throughout. Define abbreviations at first use. Spell out numbers below 10 except with units.

All authors must disclose potential conflicts including pharmaceutical industry relationships, consulting arrangements, and grant support. Complete ICMJE disclosure forms are required. Describe the role of industry sponsors in study design, data collection, analysis, and manuscript preparation.

All authors must meet ICMJE criteria: substantial contributions to conception/design, data acquisition/analysis, manuscript drafting/revision, and final approval. Contributors not meeting criteria should be acknowledged. Report author contributions using CRediT taxonomy.

Extended data tables, additional figures, video content, and detailed protocols may be submitted as supplementary materials. Supplementary files should be clearly labeled and referenced in the main text. Large datasets should be deposited in appropriate repositories with access information provided. Consider ADNI, NACC, or other dementia-specific repositories.

• Corrections and clarifications processed promptly
• Authors may deposit in institutional repositories immediately
• DOI ensures permanent citation linking
• Social media promotion supported

Double-blind review by 2-3 dementia experts. Target first decision within 21 days. Constructive feedback supports manuscript improvement.

Authors typically have 30 days to complete minor revisions and 60 days for major revisions. Submit a point-by-point response letter addressing each reviewer comment. Track changes should be visible in the revised manuscript. If unable to meet deadlines, contact the editorial office promptly.

Corresponding authors will receive proofs for review within 5 business days of acceptance. Respond promptly within 48 hours with corrections limited to typographical errors. Substantive changes require editorial approval. Accepted articles are published online within 7 business days of proof approval with full DOI and citation information.

All articles are published under Creative Commons licenses ensuring compliance with major funder mandates including NIH, Wellcome Trust, Alzheimer's Association, and European Research Council. Authors retain copyright while granting JART publication rights. Immediate deposit in PubMed Central and institutional repositories is permitted.

JART supports research reproducibility through detailed methodology reporting, data sharing encouragement, and protocol transparency. Consider pre-registration for clinical trials and confirmatory studies. Report negative results where they contribute to scientific understanding. Replication studies addressing seminal Alzheimer's findings are welcome. We encourage transparent reporting of all results including null findings.

For specific questions about manuscript preparation, study design, or reporting requirements, contact [email protected].